Updated Overall Survival Analysis of the DECISION Trial

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, discusses the updated overall survival analysis of the phase III DECISION trial, which looked at sorafenib for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC).

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, discusses the updated overall survival analysis of the phase III DECISION trial, which looked at sorafenib for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC).

Clinical Pearls:

  • The primary endpoint of the DECISION trial was reached last year, which showed an improvement from 5.8 months to 10.8 months in the sorafenib arm.
  • Overall survival, which was the secondary endpoint in the trial, was a challenging endpoint to reach because 75% of the patients on the study crossed over from the placebo arm to the sorafenib arm.
  • The initial analysis did not show a large difference between the placebo arm and the sorafenib arm.
  • An additional analysis was presented that accounted for the crossover, but the data is still not statistically significant.

<<<

View more from the 2014 ASCO Annual Meeting